FDA OKs 1st targeted drug for common lung cancer mutation

0
9

FAIRLESS HILLS, PA. (AP) — U.S. regulators have approved the first medicine for patients with the most common type of lung cancer whose tumors have a genetic mutation long considered untreatable with drugs. The Food and Drug Administration on Friday said it’s approved Amgen’s drug Lumakras for non-small cell lung cancer patients with the mutation whose cancer worsened after initial treatment with different drugs. This is the first targeted therapy for tumors with a so-called KRAS mutation, which affects cell growth and division, and is found in many cancer types.  

The post FDA OKs 1st targeted drug for common lung cancer mutation appeared first on WEEK.

LEAVE A REPLY

Please enter your comment!
Please enter your name here